NEW YORK - eTradeWire -- Manhattan BioSolutions, Inc. ("Manhattan Bio" or "MABS"), an emerging biotechnology company developing new classes of precision biologics, today announced its selection for Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator 2025 Cohort Program. This selective program connects innovative biotech companies with MSK's world-class clinical and translational experts to explore potential collaboration pathways for advancing novel cancer therapeutics.

As one of the world's foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education, and discovery. Through the MSK Therapeutics Accelerator Cohort program, Manhattan Bio is engaging with MSK clinicians and translational scientists to explore potential synergies for advancing the company's proprietary legumain (LEG)-cleavable antibody-drug conjugate (ADC) platform. These discussions provide valuable insights into clinical development pathways, regulatory strategies, and potential applications for addressing high unmet medical needs in oncology.

More on eTradeWire News

• When Words Ignite : The Transformative Power of a Single Motivational Speech
• MPRDesigns Named a Top Creative Design and Marketing Firm for 2026 by 50Pros
• Solano Way Auto Repair – Concord's Trusted Five-Star Auto Repair Shop
• Career Communications Group Launches White-Label Virtual and Digital Twin Job Fairs Powered by Collin AI and Collin Chat
• Justin Calabrese Brings Mental Health to Times Square: "There's No Price on Saving a Life"

Manhattan Bio's LEG-cleavable technology directly addresses premature payload release—a critical limitation facing current-generation ADCs that often leads to off-target toxicity and narrow therapeutic windows. The company's LEG-TOP1i ADCs have demonstrated complete tumor regression with strong durability in multiple difficult-to-treat solid tumor xenograft models, representing a potentially significant advancement over certain existing ADC technologies.

"Being selected for the MSK Therapeutics Accelerator Cohort provides an exceptional opportunity to engage with world-leading clinical and translational experts," stated Zev Gechtman, Ph.D, Scientific Director at Manhattan BioSolutions. "These discussions are helping us understand how our platform's enhanced stability and tumor-selective activation could translate into meaningful improvements for patients facing difficult-to-treat malignancies."

"We are excited to welcome Manhattan BioSolutions into the cohort program," stated Eileen Flowers, PhD, Director, Technology Development & Licensing, in the Office of Entrepreneurship and Commercialization at MSK. The MSK Therapeutics Accelerator 2025 Cohort program brought together 10 innovative biotech companies with MSK investigators and commercialization strategists to explore potential collaborations for co-developing targeted cancer therapies. The program is designed to facilitate tailored mentorship with MSK faculty and provide structured introductions to MSK's translational and clinical facilities, with the goal of defining potential pathways for formal partnership through the MSK Therapeutics Accelerator. For more information about the MSK Therapeutics Accelerator, visit: https://www.mskcc.org/commercialization/programs-accelerators/msk-therapeutics-accelerator

More on eTradeWire News

• Quantum Teleportation 2026: Will You Be Part of the New 1% — or Left Behind?
• The Help Group's 29th Annual Summit
• "Vancouver brand is selling $10,000 T-shirts , and they only have 10 left available for this year!"
• Southwest Florida River Wildlife Cams Offer Rare Glimpse Into Florida's Wild Side
• Harry Chapin Food Bank collecting turkeys, hams for Thanksgiving meals

About Manhattan BioSolutions
Manhattan BioSolutions, Inc., is a privately held biotechnology company focused on the development of biologic therapies targeting host defense pathways for the treatment of advanced cancers. The company advances next-generation antibody-drug conjugates (ADCs) - through collaborations with leading academic institutions. Learn more at manhattanbiosolutions.com and follow Manhattan BioSolutions on LinkedIn (https://www.linkedin.com/company/manhattanbio/) or Twitter (https://x.com/TheManhattanBio).